BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work
Waltham, MA-based Deciphera Therapeutics has been carefully tracking the early-stage progress it’s been making with its lead drug, a pan-KIT and PDGFR inhibitor dubbed DCC-2618. And this morning, the biotech announced that it has banked a $52 million C round to keep fueling its growing pipeline efforts.
Viking Global Investors, Redmile Group and Sphera Global Healthcare Fund led the round, joined by Deciphera’s existing investors including New Leaf Venture Partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.